Brawn Biotech Limited announced the appointment of new auditors following its board meeting held on March 25, 2026. The company has strengthened its governance framework by appointing key auditing professionals for the financial year 2025-26, in compliance with regulatory requirements.

Board Meeting Outcomes

The board meeting, which commenced at 11:00 A.M. and concluded at 11:30 A.M., addressed critical auditing appointments based on recommendations from the Audit Committee. The decisions were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Secretarial Auditor Appointment

The company appointed Mr. Viney, a practicing Company Secretary, as its Secretarial Auditor for the financial year 2025-26. Mr. Viney holds Certificate of Practice number 28263 and is an Associate Member of the Institute of Company Secretaries of India (ICSI).

Mr. Viney brings extensive expertise in corporate laws, securities laws, and compliance management. His professional experience includes handling secretarial audits, corporate restructuring, due diligence, FEMA compliances, and SEBI-related matters including LODR and PIT Regulations. He has assisted various listed and unlisted companies in ensuring statutory compliance, drafting corporate documents, and representing clients before regulatory authorities.

Internal Auditor Appointment

Brawn Biotech Limited also appointed M/s Sahil Pasricha & Associates as Internal Auditors for the financial year 2025-26. The firm, registered with FRN: 026379N, is a chartered accountant firm offering comprehensive auditing and consultancy services.

The firm provides a full range of services including:

• Audit under Companies Act
• Income Tax and GST Audit
• Delhi VAT Act compliance
• Internal Audit services
• Taxation consultancy covering Income Tax, GST, Sales Tax, and Service Tax
• Company Law matters and Labour Laws compliance

Regulatory Compliance

Both appointments were made in accordance with SEBI regulations and the Master Circular vide no. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The appointments reflect the company's commitment to maintaining robust governance standards and regulatory compliance for the financial year 2025-26.

Brawn Biotech Limited has announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

The pharmaceutical company reported its Q3 FY26 financial performance with the following key metrics:

Expense Structure

The company's expense breakdown for the quarter included employee benefit expenses, depreciation and amortization expenses, finance costs, and other operational expenses. The total expenses for Q3 FY26 were managed within the operational framework of the pharmaceutical business.

Earnings Per Share

The company reported earnings per share metrics for the quarter:

Corporate Information

Brawn Biotech Limited operates primarily in the pharmaceutical business sector. The company's registered office is located at C-64, Lajpat Nagar-1, New Delhi 110024, with manufacturing works at Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram, Haryana.

Regulatory Compliance

The financial results were prepared in compliance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. The results were reviewed by statutory auditors Rajiv Udai & Associates, Chartered Accountants, and approved by the Board of Directors at a meeting held on February 14, 2026.

The company's CFO has certified the financial results under Regulation 33(2)(a) of SEBI (LODR) Regulations, 2015, confirming that the statements present a true and fair view of the entity's affairs and comply with existing accounting standards and applicable regulations.